MindWalk Holdings Corp., a Bio-Native AI company, has been added to the Russell 3000E Index, effective after the U.S. market close on June 26, 2026. The inclusion is part of the FTSE Russell June 2026 semi-annual Russell US Indexes Reconstitution. Membership was reconfirmed in index data published on June 29, 2026. This addition expands the company's visibility among institutional investors and broadens its eligibility for index-tracking funds managing approximately $12.2 trillion in benchmarked assets.

Index Reconstitution Details

The Russell 3000E Index is FTSE Russell's broadest measure of the U.S. equity market, covering up to the 4,000 largest U.S.-domiciled public companies by market capitalization. Inclusion is determined using market capitalization as of the rank date, with no application or fee required. The reconstitution process occurs semi-annually in June and December, ensuring the index accurately reflects the current market landscape.

Key Dates

Jennifer Bath, Ph.D., Chief Executive Officer and President of MindWalk Holdings Corp., stated that being added to the index is a meaningful visibility milestone. She noted that it places the company in front of a broader set of institutional investors and signals that the market is starting to price the infrastructure layer beneath biological AI.

MindWalk's stock trades on the NASDAQ under the ticker symbol HYFT. The company builds BioIntelligence infrastructure, integrating AI, data, and advanced wet lab capabilities. Its core technology includes HYFT fingerprints spanning sequence and structural biology, forming a continuously evolving biological representation of 660 million patterns and 25 billion relationships.

MindWalk Holdings Corp. President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones alongside Absci and a leading AI compute provider on June 15, 2026. The panel, "Partnering to Power the New Era of Drug Discovery," is part of Jones AI Day and will explore how the convergence of high-performance compute, native biological knowledge representations, and generative AI can dismantle barriers in drug discovery, such as prolonged screening timelines and historically undruggable targets.

MindWalk's Technology Approach

MindWalk is a biology company that built AI on top of 25 years of wet-lab expertise. Its HYFT® technology powers ReefIQ™, the biological context layer for life sciences, which enriches biological data at ingestion and connects it across a continuously evolving knowledge representation of 660 million biological patterns and 25 billion relationships. The LensAI™ platform serves as the reasoning and application layer on top of this infrastructure. The architecture is designed to keep AI models and autonomous agents from hallucinating in high-consequence drug discovery workflows by grounding predictions in evolutionary constraint rather than statistical correlation.

Panel Discussion Focus

Dr. Bath is expected to discuss why the durable asset in biological AI is the enriched context layer rather than any individual model, and how that layer makes agentic AI trustworthy enough to deploy in regulated workflows. LensAI™ is currently in contracted, recurring arrangements with life-sciences customers. The panel will be moderated by Jones Research Senior Research Analysts Dr. Debanjana Chatterjee and Dr. Danya Ben-Hail.

Event and Participant Details

The event is scheduled for Monday, June 15, 2026, at 12:00 p.m. ET and is hosted as part of Jones AI Day, which runs from 10:30 a.m. to 2:30 p.m. ET. Registration is open to institutional investors through Jones. The panelists include Dr. Jennifer Bath of MindWalk, Sean McClain, Founder and CEO of Absci, and senior healthcare and life-science strategy leadership from the AI compute provider.